Previous studies suggested an association between 1425G/A polymorphism in PRKCH and stroke risk, but the results were inconsistent. To obtain a more precise estimation, we carried out a meta-analysis to analyze the effect of 1425G/A SNP in PRKCH on stroke risk. We searched PubMed, ISI Web of Science, Chinese Biomedical Database, China National Knowledge Infrastructure and WANFANG Data for all eligible case-control studies through April 2014. The odds ratios (ORs), together with the 95% confidence intervals (CIs), were calculated to evaluate the strength of association between 1425G/A SNP and stroke risk. Overall, seven eligible studies involving a total of 4,574 cases and 5,471 controls were included in our meta-analysis. The results showed that the variant genotypes of 1425G/A polymorphism in PRKCH were significantly associated with a higher risk of stroke in all genetic models (GA vs. GG: OR 1.35, 95% CI 1.24-1.47, P < 0.001; AA vs. GG: OR 1.50, 95% CI 1.24-1.82, P < 0.001; GA/AA vs. GG: OR 1.37, 95% CI 1.26-1.49, P < 0.001; AA vs.
Ga/gg: OR 1.35, 95% CI 1.12-1.62, P = 0.002; A vs. G: OR 1.29, 95% CI 1.21-1.39, P < 0.001). In the subgroup analysis, significantly increased risks were also observed for ischemic stroke, larger sample size (>1,000) and population-based studies. The result of our meta-analysis indicated that the 1425G/A SNP in PRKCH may contribute to susceptibility of stroke, especially for ischemic stroke.